首頁 > 市場調查報告書 > 製藥

自體免疫疾病

市場調查報告書

商品編碼

1918104

自體免疫疾病檢測市場—2026-2031年預測

Autoimmune Disease Testing Market - Forecast from 2026 to 2031

出版日期: 2026年01月14日 | 出版商:

Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

自體免疫疾病檢測市場預計將從 2025 年的 58.43 億美元成長到 2031 年的 89.29 億美元，複合年成長率為 7.32%。

自體免疫疾病檢測市場正經歷顯著成長，這主要受疾病盛行率上升和診斷技術進步的推動。自體免疫疾病的特徵是身體對自身組織產生異常免疫反應，破壞正常的免疫穩態，通常涉及發炎、自體抗體和自體反應性T細胞。由於這些疾病的複雜性以及缺乏單一的確診檢測方法，因此需要先進的診斷方法來輔助患者管理、預後評估和器官受累情況的判斷。

市場成長的關鍵促進因素是全球自體免疫疾病盛行率的上升。兒童族群中第1型糖尿病和老年族群中類風濕性關節炎（RA）等疾病發生率的增加，持續推高了對診斷解決方案的需求。全球人口老化進一步加速了這一趨勢，老化擴大了RA等與老齡化相關的自體免疫疾病的患者群體，直接推動了檢測需求。

同時，民眾和醫療專業人員對自體免疫疾病的認知不斷提高，也推動了市場成長。諸如特定宣傳月和以患者為中心的教育宣傳活動等舉措，提高了人們對疾病症狀的認知，並強調了早期診斷的重要性。這種對早期檢測的日益重視對於改善患者預後至關重要，也是推動診斷測試需求的主要因素。

市場按檢測類型和疾病進一步細分，某些領域展現出顯著的成長潛力。抗核抗體 (ANA) 檢測預計將成為高成長細分市場，因為它有助於在臨床症狀出現之前早期發現疾病。與傳統方法相比，ANA 檢測操作簡單且準確，已被廣泛採用作為一線檢測方法，直接推動了市場擴張。同樣，全身性紅斑性狼瘡(SLE) 檢測細分市場也預計將佔據相當大的市場佔有率。對複雜系統性自體免疫疾病診斷需求的不斷成長，正促使診斷公司開發和推出專門的檢測方法，從而豐富其產品線並加速市場成長。

全球免疫診斷市場涵蓋醫院、診斷實驗室和研究機構等，為自體免疫檢測提供了堅實的基礎。醫院仍然是主要的終端用戶，其綜合診療模式整合了先進的診斷和治療，因此備受認可。在公共和私人資金的支持下，這些機構不斷採用尖端方法和醫療設備，從而提高了醫療服務標準，並維持了高水準的檢測量。

從地理上看，亞太地區預計將主導自體免疫疾病檢測市場。這一主導地位歸因於該地區某些自體免疫疾病（例如全身性紅斑性狼瘡）的高發病率和不斷上升的趨勢。市場參與企業的策略性舉措、持續的研發投入以及醫療基礎設施的不斷完善是鞏固該地區市場佔有率的關鍵因素。

競爭格局相對集中，主要由雅培、生物梅里埃和賽默飛世爾科技等全球知名企業主導。這些公司透過持續的研發投入和策略擴張，維持了市場領先地位。一個顯著的趨勢是，診斷公司正與醫院網路建立策略聯盟，以滿足不同地區龐大的患者群體和多樣化的檢測需求。預計這項策略將持續發展並影響市場走向。這種對創新和合作的重視凸顯了市場的活力和應對力，並預示著其將持續擴張。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 德國
- 法國
- 英國
- 西班牙
- 義大利
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 印尼
- 泰國
- 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
企業合併、協議、商業合作
競爭對手儀錶板

第11章：公司簡介

F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Abbott
Werfen
Trinity Biotech Plc
Bio-Rad Laboratories, Inc.
Danaher Corporation
Exagen Inc

第12章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
分析方法
簡稱

簡介目錄

Product Code: KSI061615574

The autoimmune disease testing market is projected to expand at a 7.32% CAGR, attaining USD 8.929 billion in 2031 from USD 5.843 billion in 2025.

The autoimmune disease testing market is experiencing significant growth, driven by increasing disease prevalence and advancements in diagnostic capabilities. Autoimmune diseases, characterized by an aberrant immune response against the body's own tissues, disrupt normal immunological homeostasis and are typically marked by inflammation, autoantibodies, and self-reactive T cells. The complexity of these conditions, for which no single definitive laboratory test exists, necessitates a sophisticated diagnostic approach to aid in patient management, prognosis, and assessment of organ involvement.

A primary catalyst for market expansion is the rising global prevalence of autoimmune disorders. The increasing incidence of conditions such as type 1 diabetes in pediatric populations and rheumatoid arthritis (RA) in the growing geriatric demographic is creating a substantial and sustained demand for diagnostic solutions. This trend is compounded by a global aging population, which presents a larger patient base for age-related autoimmune conditions like RA, thereby directly fueling the need for testing.

Concurrently, heightened awareness of autoimmune diseases among both the public and healthcare professionals is bolstering market growth. Initiatives such as dedicated awareness months and patient-focused education campaigns are improving recognition of disease symptoms and underscoring the importance of early diagnosis. This growing emphasis on early detection is critical for improving patient outcomes and is a key factor propelling the demand for diagnostic testing.

The market is further segmented by test type and disease focus, with specific areas demonstrating pronounced growth potential. The antinuclear antibody (ANA) test is anticipated to be a high-growth segment due to its utility in early disease detection, often before clinical symptoms manifest. The test's procedural simplicity and accuracy compared to older methods make it a widely adopted first-line tool, directly contributing to market expansion. Similarly, the segment for Systemic Lupus Erythematosus (SLE) testing is expected to hold a significant market share. The drive to diagnose complex systemic autoimmune disorders has prompted diagnostic companies to develop and launch specialized assays, thereby enriching the product landscape and accelerating market growth.

The broader global immune diagnostics market, encompassing hospitals, diagnostic facilities, and research organizations, provides a robust infrastructure for autoimmune testing. Hospitals remain the dominant end-user setting, favored for their comprehensive care models that integrate advanced diagnostics with treatment. The continuous adoption of cutting-edge procedures and medical equipment within these institutions, often supported by public and private funding, elevates the standard of care and sustains a high volume of testing.

Geographically, the Asia-Pacific region is anticipated to dominate the autoimmune disease testing market. This leadership is attributed to a high and growing prevalence of specific autoimmune conditions, such as systemic lupus erythematosus, within the region. Strategic initiatives by market participants, ongoing research investments, and the continuous development of healthcare infrastructure are key factors consolidating the region's substantial market share.

The competitive landscape is relatively concentrated and features established global players such as Abbott Laboratories, BioMerieux, and Thermo Fisher Scientific. These companies maintain their market leadership through sustained investment in research and development and strategic expansion efforts. A notable trend involves diagnostic firms forming strategic alliances with hospital networks to address high patient volumes and diverse testing needs across different geographies, a strategy expected to persist and shape the market's trajectory. This focus on innovation and collaboration underscores a dynamic and responsive market poised for continued expansion.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Autoimmune Disease Testing Market Segmentation:

By Product Type
Instruments
Analyzers
Flow Cytometers
Others
Reagents & Consumables
By Test Type
Antinuclear Antibody (ANA) Test
C-Reactive Protein Test
Rheumatoid Factor
Anti-CCP Test
Others
By Disease Type
Rheumatoid Arthritis
Lupus
Scleroderma
Vasculitis
Inflammatory Bowel Disease
Others
By End-User
Hospitals & Clinics
Diagnostic Centers
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Italy
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AUTOIMMUNE DISEASE TESTING MARKET BY PRODUCT TYPE

5.1. Introduction
5.2. Instruments
- 5.2.1. Analyzers
- 5.2.2. Flow Crytometers
- 5.2.3. Others
5.3. Reagents & Consumables

6. AUTOIMMUNE DISEASE TESTING MARKET BY TEST TYPE

6.1. Introduction
6.2. Antinuclear Antibody (ANA) Test
6.3. C-Reactive Protein Test
6.4. Rheumatoid Factor
6.5. Anti-CCP Test
6.6. Others

7. AUTOIMMUNE DISEASE TESTING MARKET BY DISEASE TYPE

7.1. Introduction
7.2. Rheumatoid Arthritis
7.3. Lupus
7.4. Scleroderma
7.5. Vasculitis
7.6. Inflammatory Bowel Disease
7.7. Others

8. AUTOIMMUNE DISEASE TESTING MARKET BY END-USER

8.1. Introduction
8.2. Hospitals & Clinics
8.3. Diagnostic Centers
8.4. Others

9. AUTOIMMUNE DISEASE TESTING MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Spain
- 9.4.5. Italy
- 9.4.6. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. India
- 9.6.3. Japan
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others